267 results on '"Bundred, Nigel J."'
Search Results
2. Ductal Carcinoma In Situ
3. Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial
4. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial
5. Supplementary Material from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
6. Supplementary Figure 3 from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
7. Supplementary Figure 2 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
8. Supplementary Methods from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
9. Supplementary Figure 2 from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
10. Supplementary Figure 1 from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
11. Supplementary Figure 1 from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
12. REMARK checklist from Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
13. Supplementary Figure Legend from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
14. Data from Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
15. Supplementary Table 2 from Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
16. Supplementary Table 1 from Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
17. Supplementary Figure Legend from Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
18. Supplementary Figure 1 from Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
19. Supplementary Table 3 from Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
20. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
21. Response and Resistance to the Endocrine Prevention of Breast Cancer
22. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis
23. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis
24. Ductal Carcinoma In Situ
25. Ductal Carcinoma In Situ
26. Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer
27. Ductal carcinoma in situ of the breast
28. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
29. Abstract P3-18-07: Margin involvement in invasive breast cancer leads to increased distant recurrence after breast conservation: Systematic review
30. Prevention of lymphoedema after axillary clearance by external compression sleeves PLACE randomised trial results. Effects of high BMI.
31. Early Discharge after Surgery for Breast Cancer
32. Is axillary lymph node clearance required in node-positive breast cancer?
33. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
34. Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
35. Treatment of ductal carcinoma in situ
36. Ductal Carcinoma In Situ
37. Contributors
38. Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial
39. Idiopathic Granulomatous Mastitis: A 25-Year Experience
40. Additional file 1 of Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial
41. Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial
42. How useful are molecular assays in breast cancer in the elderly?
43. The management of preinvasive breast cancer
44. Response and Resistance to the Endocrine Prevention of Breast Cancer
45. 14 - Treatment of ductal carcinoma in situ
46. Residual disease after mastectomy
47. Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre‐invasive phenomena that is prognostic in invasion
48. Aromatase inhibitors and bone health
49. Effective Inhibition of Aromatase Inhibitor-Associated Bone Loss by Zoledronic Acid in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole: Zo-Fast Study Results
50. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.